Next Article in Journal
Proteoglycan Combined with Hyaluronic Acid and Hydrolyzed Collagen Restores the Skin Barrier in Mild Atopic Dermatitis and Dry, Eczema-Prone Skin: A Pilot Study
Next Article in Special Issue
Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report
Previous Article in Journal
Mechanisms of Connexin Regulating Peptides
Previous Article in Special Issue
Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles
 
 
Article
Peer-Review Record

Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination

Int. J. Mol. Sci. 2021, 22(19), 10188; https://doi.org/10.3390/ijms221910188
by Alexandra Herrmann, Doris Jungnickl, Arne Cordsmeier, Antonia Sophia Peter, Klaus Ãœberla and Armin Ensser *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2021, 22(19), 10188; https://doi.org/10.3390/ijms221910188
Submission received: 17 August 2021 / Revised: 17 September 2021 / Accepted: 17 September 2021 / Published: 22 September 2021

Round 1

Reviewer 1 Report

The proposed research is very interesting and the results obtained seem to be able to manipulate SARS-CoV-2 in the lab without risks allowing the employment of biological knowledge.

I don't have any specific comments, but I encourage a deep revision of the text because are present several typos and grammatical errors.

 

 

Author Response

We are thankful to the reviewer for the effort and favorable comments. The text was revised accordingly and several typos and grammatical errors were corrected.

Reviewer 2 Report

The authors present interesting research on the clonic of a passage-free SARS-CoV-2 genome, by applying a BAC-based Red combination, in order to produce a possible tool to facilitate studies on SARS-CoV-2.

The paper presents the assembly of pBelo-SARS-CoV-2, re recovery of recombinant SARS-CoV-2, then the generation and characterization of recSARS-CoV-2 reporter and marker viruses. Finally, the authors assessed the antiviral activity of the two reference drugs (redemsivir and GC376) against the recombinant virus.  

The manuscript is well written, with good use of the English language. The results are supported by clear pictures and graphs. The methods are well presented. 

Besides some minor editing and avoiding using abbreviations in keywords, I have no other recommendations for the author.

Author Response

We are thankful to the reviewer for the effort and very favorable comments. The text was revised accordingly, the abbreviation in keywords removed and several typos and grammatical errors corrected.

Back to TopTop